Phio Pharmaceuticals Corp. announced on October 7, 2024, that it would present data about its proprietary INTASYL platform and INTASYL compounds at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting on October 8th. The presentation highlighted how INTASYL compounds offer precise targeting by silencing mRNA, significantly enhancing immune responses against cancer. This includes their effectiveness as intratumoral injections and as excipients during immune cell expansion for adoptive cell therapy.
Specific INTASYL compounds discussed included PH-762, which silences PD-1 to improve therapeutic efficacy in vivo, and PH-894, which precisely silences BRD4 to enhance tumor cell immunogenicity and induce apoptosis. Additionally, the presentation covered PH-804, which silences TIGIT in NK cells to enhance their activation and cytokine release, and PH-905, which silences CBLB to increase NK cell cytotoxicity and proliferation.
A key differentiator emphasized was INTASYL's efficient delivery system, which requires no special formulations to streamline siRNA delivery to target cells. This self-delivering nature simplifies administration and potentially reduces manufacturing hurdles, positioning INTASYL as a versatile and innovative technology in cancer immunotherapy.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.